Skip to content

ENHANCING SPEED & QUALITY IN CELL & GENE THERAPY MANUFACTURING FOR THE DACH REGION

17-18 February 2027 Munich, Germany
REGISTER YOUR INTEREST
Co-located Events
OPX DACH 2027 Logo-04
BioManuDACH 2027 LOGO Square White

 Bringing together 250+ CGT manufacturing, process development, technology, regulatory and operations leaders across the DACH region to tackle the challenges of scaling, automation, GMP manufacturing, process optimisation and commercialisation. 

WHO

 250+ cell & gene therapy manufacturing leaders, operators, regulators and technology partners from across the DACH ecosystem. 

WHAT

 DACH’s focused forum on the practical execution of cell and gene therapy manufacturing — from process transfer and automation to GMP scale-up, biosafety and supply continuity. 

WHY
 Tackle the critical challenges holding CGT manufacturing back: capacity, regulatory complexity, cost, technology transition and commercial scale-up. 
icons cgw welcome_1
0 +

Senior Attendees

icons cgw welcome-02
0 +

Expert Speakers

bwd2026-company-ezgifcom-speed.bb78342dfc94
0 +

Companies Represented

What is new in 2027?
This year introduces the DACH Bioprocessing Excellence Awards, recognising manufacturing innovation, operational excellence, and leadership across cell & gene therapy, biologics, and oligos & peptides.
The programme brings cell & gene therapy, biologics, and oligos & peptides together in one agenda, reflecting the shift toward multi-platform and hybrid manufacturing models.
There is a stronger emphasis on late-stage CMC, tech transfer, GMP readiness, and cost-of-goods, aligning discussions with real-world commercialisation challenges.
New sessions highlight digital and automated manufacturing, including digital twins, PAT, real-time release testing, and closed-system operations.
The agenda places greater focus on patient-centric and decentralized CGT models, covering autologous manufacturing, point-of-care production, and chain of identity.
Discussions are tailored to DACH-specific operational and sustainability priorities, including facility design, supplier risk, energy efficiency, and regional regulatory expectations.

AGENDA AT A GLANCE

Day 1 | 17 February 2027
Day 2 | 18 February 2027
CGTDACH 2027 LOGO CGTDACH 2027 LOGO
Commercialising Cell & Gene Therapies: Scaling for Global Success
Bridging the CGT Scale-Up & Tech Transfer Gap
Networking Break
Scaling Cell Therapy Manufacturing
Quality, GMP & Regulatory Control in CGT Manufacturing
Lunch
Overcoming Bottlenecks in Viral Vector Manufacturing
Novel Biosafety and Contamination
Networking Break
Industry Roundtables: The Future of CGT Manufacturing
Supply Chain, Logistics & Commercial Readiness
End of Conference Day 1 End of Conference
Day 1 | 17 February 2027
CGTDACH 2027 LOGO
Commercialising Cell & Gene Therapies: Scaling for Global Success
Networking Break
Scaling Cell Therapy Manufacturing
Lunch
Overcoming Bottlenecks in Viral Vector Manufacturing
Networking Break
Industry Roundtables: The Future of CGT Manufacturing
End of Conference Day 1
Day 2 | 18 February 2027
CGTDACH 2027 LOGO
Bridging the CGT Scale-Up & Tech Transfer Gap
Networking Break
Quality, GMP & Regulatory Control in CGT Manufacturing
Lunch
Novel Biosafety and Contamination
Networking Break
Supply Chain, Logistics & Commercial Readiness
End of Conference

AGENDA

DAY 1
17 February 2027
VIEW DAY 1 VIEW DAY 2
08:00 Registration & Coffee
08:50

Chairman’s Welcome Address

Nicoletta Loggia Chief Technology Officer, Orchard Therapeutics, Switzerland
Commercialising Cell & Gene Therapies: Scaling for Global Success
09:00

Scaling Viral Vector & Cell Therapy Manufacturing for Commercial Readiness

  • Overcoming scale-up bottlenecks in viral vector production (lentiviral, AAV)
  • Managing process consistency from development to GMP manufacturing
  • Manufacturing considerations across T-cell, NK-cell, and CD34 stem cell therapies
  • Bridging the gap between small-scale development and industrial production
Nicoletta Loggia Chief Technology Officer, Orchard Therapeutics, Switzerland
09:30
Solution Provider
Reserved for Solution Provider
10:00
Panel Discussion

Building Sustainable CGT Business Models: From Clinical to Commercial

  • Impact of funding constraints and milestone-driven investment
  • Cost of goods and manufacturing scalability challenges
  • Ensuring long-term operational and commercial sustainability
  • Aligning manufacturing strategy with market access and growth
Panelists
Chris Baldwin Vice President, Manufacturing and Supply, Resolution Therapeutics, UK Parag Kumthekar Lead Gene Therapy Downstream Team, UCB, Belgium
10:30 Networking Break
Scaling Cell Therapy Manufacturing
11:10

Scaling Non-Viral T-Cell Engineering: Bridging Process Development and GMP Manufacturing (TBC)

  • Translation from small-scale development to clinical manufacturing
  • Large-scale CRISPR knock-in and knock-out
  • Maintaining editing efficiency, viability and cell quality
  • Reproducibility across different donors and starting materials
Gulbengu Kuzgun Yuksel Network Head of Quality Cell & Gene Therapy, Roche, Switzerland
11:40
Solution Provider
Reserved for Solution Provider
12:10

Scaling CAR-T Manufacturing: From Clinical Success to Commercial Delivery

  • Overcoming manufacturing bottlenecks in autologous CAR-T production
  • Improving vein-to-vein timelines through process optimisation
  • Increasing manufacturing capacity while maintaining product quality
  • Preparing CAR-T platforms for sustainable commercial supply
13:00 Lunch
Overcoming Bottlenecks in Viral Vector Manufacturing
14:00

Scaling Viral Vector Manufacturing: From Development to GMP Production

  • Addressing scale-up challenges in lentiviral and AAV production
  • Managing process variability between R&D and GMP environments
  • Bridging development processes with commercial manufacturing requirements
  • Reducing risk during tech transfer and engineering runs
Parag Kumthekar Lead Gene Therapy Downstream Team, UCB, Belgium
14:30
Solution Provider
Reserved for Solution Provider
15:00

Improving Yield, Consistency & Cost Efficiency in Viral Vector Production

  • Enhancing process robustness and reproducibility at scale
  • Tackling low yields in complex vector manufacturing processes
  • Optimising upstream and downstream performance for efficiency gains
  • Balancing cost pressures with clinical and commercial demand
15:30 Networking Break
16:00
Roundtable Discussion
 Can CGTs Become Truly Commercially Viable?  
Exploring Advances in Viral Vector Manufacturing (TBC)
Parag Kumthekar Lead Gene Therapy Downstream Team, UCB, Belgium
 What Does “GMP” Really Mean for Early-Phase ATMPs?  
 Industrialising CGT: Automation vs Practical Reality  
 Building Scalable CGT Manufacturing Models for the Next Decade (TBC) 
Gulbengu Kuzgun Yuksel Network Head of Quality Cell & Gene Therapy, Roche, Switzerland
17:00 Cocktail Reception
17:15 End of Conference Day 1
DAY 2
18 February 2027
VIEW DAY 1 VIEW DAY 2
08:00 Registration & Coffee
08:50

Chairman’s Welcome Address

Bridging the CGT Scale-Up & Tech Transfer Gap
09:00

Why CGT Tech Transfer Fails — From R&D to GMP Reality

  • Fundamental mismatch between lab-scale and GMP manufacturing environments
  • Limited opportunity for full-scale optimisation due to cost and material constraints
  • Environmental and operational differences between development and production sites
  • Hidden failure points emerging only during GMP execution
Marion Hitchcock Managing Director Gene & Cell Therapies Incubator, Bayer, Germany
09:30
Solution Provider
Reserved for Solution Provider
10:00

Manufacturing Strategies Across CD34 Stem Cell, T-Cell & NK-Cell Therapies

  • Platform-specific manufacturing challenges across CD34 stem cells, T- Cells, and NK-Cells
  • Optimising process development and scale-up for different cell therapy modalities
  • Technology transfer considerations from clinical to commercial manufacturing
  • Ensuring process robustness, comparability, and manufacturing consistency across diverse cell therapy platforms
10:30 Networking Break
Quality, GMP & Regulatory Control in CGT Manufacturing
11:10
Panel Discussion

The Future of CAR-T Manufacturing: In Vivo vs Ex Vivo Approaches Towards 2030

  • In vivo vs ex vivo: how quickly will the manufacturing model evolve?
  • 2030, 2035 or 2040: when could in vivo CAR-T become commercially viable?
  • Cost & scalability: Can  in vivo approaches reduce cost per patient and improve accessibility?
  • Safety: managing the risks of in vivo vector delivery and long-term effects.
Panelists
Bart Van Waeyenberge EMEA Head of CAR T Operations, Johnson & Johnson, Belgium
11:40
Solution Provider
Reserved for Solution Provider
12:10

Navigating GMP & Regulatory Complexity in Cell & Gene Therapy

  • Non-harmonised expectations across EMA vs FDA and global regulators
  • Evolving GMP expectations for early-phase vs commercial CGT manufacturing
  • Assay validation, comparability, and starting material scrutiny challenges
  • Regulatory uncertainty during tech transfer from academic to GMP environments
13:00 Lunch
Novel Biosafety and Contamination
14:00

How can CGT manufacturers strengthen biosafety controls without slowing development?

  • Managing contamination risk across donor material, starting materials, viral vectors, and open processing steps
  • Balancing rapid methods, assay sensitivity, and GMP/regulatory expectations
  • Strengthening investigation and decision-making pathways when atypical results arise
  • Building scalable contamination-control strategies as programmes move from early clinical to commercial supply
14:30
Solution Provider
Reserved for Solution Provider
15:00

Building a Phase-Appropriate Biosafety Strategy for Cell and Gene Therapy Manufacturing

  • Defining biosafety-testing needs according to modality, process risk, and clinical stage
  • Integrating cell-bank, raw-material, in-process, and product testing into one coherent control strategy
  • Reducing turnaround-time risk while maintaining confidence in product safety and quality
  • Preparing biosafety methods and controls for tech transfer, scale-up, and commercial readiness
15:30 Networking Break
Supply Chain, Logistics & Commercial Readiness
16:00

Managing Critical Material Shortages in CGT Manufacturing

  • Viral vectors, plasmids and raw material bottlenecks
  • Long lead times and limited supplier base
  • Impact of material constraints on GMP production timelines
  • Practical mitigation strategies used by manufacturers today
16:30

What Breaks When CGTs Move from Clinical to Commercial Supply?

  • Tech transfer failures impacting supply continuity
  • Scaling manufacturing networks under GMP constraints
  • Misalignment between development timelines and manufacturing reality
  • Operational challenges in sustaining commercial supply
17:00 Closing Remarks
17:15 End of Conference Day 1

MEET THE SPEAKERS

cgtdach27
Nicoletta Loggia CHAIRMAN

Nicoletta Loggia

Chief Technology Officer
Orchard Therapeutics
Switzerland
Connect on LinkedIn
Marion Hitchcock BIG PHARMA

Marion Hitchcock

Managing Director Gene & Cell Therapies Incubator
Bayer
Germany
Connect on LinkedIn
Gulbengu Kuzgun Yuksel BIG PHARMA

Gulbengu Kuzgun Yuksel

Network Head of Quality Cell & Gene Therapy
Roche
Switzerland
Connect on LinkedIn
DACH2027_SPEAKER_Bart Van Waeyenberge BIG PHARMA

Bart Van Waeyenberge

EMEA Head of CAR T Operations
Johnson & Johnson
Belgium
Connect on LinkedIn

 Interested in Sharing Your Expertise and Insights? 

MEET THE SPEAKERS

of Co-located Events 

BioManuDACH 2027 LOGO Square White
OPX DACH 2027 Logo-04
Volker Derdau BIG PHARMA

Volker Derdau

Head Center of Excellence Isotope Chemistry, Senior Distinguished Scientist
Sanofi
Germany
Connect on LinkedIn
Baerbel Grossmann BIG PHARMA

Baerbel Grossmann

Associate Director Global Regulatory Affairs CMC Biologics
Sanofi
Germany
Connect on LinkedIn
Dr. Cecile Brocard BIG PHARMA

Dr. Cecile Brocard

Head of Downstream Development
Boehringer Ingelheim
Austria
Connect on LinkedIn
Karoline Bechtold-Peters BIG PHARMA

Karoline Bechtold-Peters

Director Science & Technology - Scientific Office/Drug Product Development/Global Biologics & CGT
Novartis
Switzerland
Connect on LinkedIn
Bettina Knapp BIG PHARMA

Bettina Knapp

Head of Digital Operations Drug Substance
Boehringer Ingelheim Pharma
Germany
Connect on LinkedIn
Alessio Epifanio BIG PHARMA

Alessio Epifanio

Director, Environmental Health, Safety & Sustainability
J&J Innovative Medicine
Italy
Connect on LinkedIn
DACH2027_SPEAKER_Carl Reens BIG PHARMA

Carl Reens

Principal Scientist, Global Chemical Development
AstraZeneca
UK
Connect on LinkedIn
DACH2027_SPEAKER_Roberto Corazza BIG PHARMA

Roberto Corazza

Operational Excellence, Digital and Strategy Director
J&J Innovative Medicine
Italy
Connect on LinkedIn

Sponsors & Media Partner

Special thanks to our event partners, without whom we would not be able to provide
this networking, learning, and collaborating platform to the community

Looking to partner with us for this event?

EXPECTED AUDIENCE SNAPSHOT
Biopharma & Big Pharma
Attendance from

Biopharma & Big Pharma

90%
Service & Solution Providers
Attendance from

Service & Solution Providers

10%

Decision Makers

Decision Makers
Others

By Geography

map_CGTDACH27 map

By Profile

Large Pharma & Biopharma Manufacturers
0%
Emerging Biotech
0%
Academia & Research Institutes
0%
Regulatory / Public Health Bodies
0%
CDMOs
0%

By Job Title

Executive Leadership (C-Suite / Founders / MDs)
0%
Process Development & MSAT
0%
R&D / Scientific
0%
Manufacturing & Operations
0%
Quality & Compliance
0%
Supply Chain & External Manufacturing
0%
Business Development & Commercial
0%
Regulatory Affairs
0%
Medical & Clinical Affairs
0%
Engineering, Automation & Digitalisation
0%
Other / General Management
0%

Targeted Attendees List

View Expanded List
SPONSORSHIP OPPORTUNITIES

Sponsorship Packages

Diamond

PACKAGE INCLUDES
  • Full-day workshop for 30 pax: room, lunch, 2 refreshment breaks, coffee / tea
  • Keynote solo presentation: 20 min + 5 min Q&A
  • 25-minute end-user client case study
  • 12 sqm exhibition space (4×3m booth + banner)
  • 1 speaker pass; 7 guest passes; 2 exhibitor passes
  • 10 onsite 1:1 meetings
  • Lead retrieval

Platinum

PACKAGE INCLUDES
  • Half-day workshop for 30 pax: room, 1 refreshment break, coffee / tea
  • Prime-billing solo presentation: 20 min + 5 min Q&A
  • 25-minute end-user client case study
  • 12 sqm exhibition space (4×3m booth + banner)
  • 1 speaker pass; 7 guest passes; 2 exhibitor passes
  • 10 onsite 1:1 meetings
  • Lead retrieval

Gold

PACKAGE INCLUDES
  • Prime-billing solo presentation: 20 min + 5 min Q&A
  • 9 sqm exhibition space (3×3m booth + banner)
  • 1 speaker pass; 5 guest passes; 2 exhibitor passes
  • 10 onsite 1:1 meetings
  • Lead retrieval

Silver (Enhanced)

PACKAGE INCLUDES
  • Solo presentation: 20 min + 5 min Q&A
  • 6 sqm exhibition space (3×2m booth + banner)
  • 1 speaker pass; 3 guest passes; 2 exhibitor passes
  • 5 onsite 1:1 meetings
  • Lead retrieval

Silver

PACKAGE INCLUDES
  • Solo presentation: 10 min + 5 min Q&A
  • 6 sqm exhibition space (3×2m booth + tabletop display)
  • 1 speaker pass; 2 guest passes; 2 exhibitor passes
  • 5 onsite 1:1 meetings
  • Lead retrieval

Bronze

PACKAGE INCLUDES
  • Solo presentation: 10 min + 5 min Q&A
  • 6 sqm exhibition space (3×2m booth)
  • 1 speaker pass; 2 guest passes
  • Lead retrieval

Exhibition + 10 Meetings

PACKAGE INCLUDES
  • 6 sqm exhibition space (3×2m booth + banner)
  • 1 guest pass; 2 exhibition passes
  • 10 onsite 1:1 meetings
  • Lead retrieval

Exhibition + 5 Meetings

PACKAGE INCLUDES
  • 6 sqm exhibition space (3×2m booth + banner)
  • 1 guest pass; 2 exhibition passes
  • 5 onsite 1:1 meetings
  • Lead retrieval

Exhibition

PACKAGE INCLUDES
  • 6 sqm exhibition space (3×2m booth + banner)
  • 1 guest pass; 2 exhibition passes
  • Lead retrieval
Who Should Sponsor?

Cell Isolation & Processing Systems

Cryopreservation, Storage & Cold Chain Logistics

Viral Vector Manufacturing

Analytical Testing, Quality Control & Release Assays

Gene Editing & Cell Engineering Technologies

Sterility Testing & Microbiology Solutions

Cell Culture Media, Reagents & Consumables

CDMOs & Contract Manufacturing Services

Cell Expansion & Bioreactor Technologies

Raw Materials, Plasmids & Critical Components

Single-Use Bioprocessing Systems

Engineering, Cleanroom & Facility Design

Process Monitoring, Automation & Digital Manufacturing

Regulatory, Validation & Quality Services

Cell Harvesting, Washing & Formulation Technologies

Chain of Identity / Chain of Custody Solutions

Aseptic Fill-Finish Solutions

Clinical Supply Chain & Logistics Providers

Sponsorship_bwd2026_icon__0004

Thought Leadership Speaking

Sponsorship_bwd2026_icon__0003

Panel Participation

Sponsorship_bwd2026_icon__0002

Solution Showcases

Sponsorship_bwd2026_icon__0001

Engagement and Visibility Opportunities

Sponsorship_bwd2026_icon__0006

Branding and Digital Visibility

Sponsorship_bwd2026_icon__0000

Exclusive Networking

DACH Series Past Partners

TESTIMONIALS
Speaker Headshot BWD2026 Heiner Apeler 2
Dr Heiner Apeler
VP Head of Biologics Development
Bayer Germany

The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.

BioOut2026_SPEAKER_John Bridgeman
John Bridgeman
CSO
Immunokey UK

Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey’s development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal. 

Speakers_photo_bwd_website_Dennis-Stelljes
Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS Switzerland

 Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I’m excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity! 

Speaker Headshot BWD2026 Andrew Kelly 2
Dr Andrew Kelly
Director, Manufacturing Technology
BMS Ireland

Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators 

Speakers_photo_bwd_website_Thomas-Villiger
Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW Switzerland

A fantastic deep dive into the DACH region’s CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together. 

Brian O'Connor | VP Global Quality, Orchard Therapeutics, UK
Brian O'Connor
VP Global Quality
Orchard Therapeutics UK

Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees. 

Alvaro Avivar-Valderas | Associate Director - Cell Therapy Technology & Product Engine, Takeda, Spain
Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda Spain

Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!

Speaker Headshot BWD2026 Steffen Schulze 2
Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche Switzerland

I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants. 

merck200
Terry Gray
Field Marketing Manager
Merck

I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.

BioUK2026_SPEAKER_Dr Warren Roche
Warren Roche
Senior Statistical Expert
Sanofi Ireland

Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event 

BWD2026 Website Headshot Speaker Michael Inglis 2
Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease Ireland

Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event.

I hope we have opportunity to connect again in the future.

Speaker Headshot BWI2026 Shada Warreth 2
Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT Ireland

 Well done on a very informative and successful event.

 

TICKETS
free_ticket_mockup_london_biomanuk26_bp_website.4564ec01ff01
From £699 + VAT
free_ticket_mockup_london_biomanuk26_ssp_website.144dadbd20be
From £2895 + VAT

VENUE

Radisson Blu Hotel, London Heathrow

140 Bath Road, Harlington, Hayes UB3 5AW, UK
Getting There Accommodation Options View the Floorplan

Travel Options

Travel options Radisson Blu Hotel, London Heathrow 140 Bath Road, Hayes, Middlesex, UB3 5AW
We look forward to welcoming you to our event at the Radisson Blu Hotel, conveniently located just minutes from Heathrow Airport. Please find travel guidance below to help you plan your journey. 
subway.286a621e9981

By London Underground

Take the London Underground Piccadilly Line toward Heathrow Airport.

  • Alight at Heathrow Terminal 2 & 3 Underground Station
  • From the station, the hotel is a short taxi or bus journey away

Estimated travel time: 45–60 minutes from central London.

bus.092fa764c07e

From Heathrow Airport

The hotel is located along Bath Road, with regular bus services connecting all terminals.

  • Local bus routes: 105, 111, 140, 285
  • Hotel Hoppa shuttle service also available
  • Alight on Bath Road, a short walk from the hotel

Estimated travel time: 10–20 minutes

taxi_2.75bc650d90cf

Taxi or Ride-Hailing

Taxis and ride-hailing services are readily available at all Heathrow terminals.

Estimated travel time: 5–10 minutes Estimated cost: £10–£20

car.e22d1548067f

By Car

The hotel is easily accessible by road:

  • Address: 140 Bath Road, Hayes, Middlesex, UB3 5AW
  • Located just off the M4 motorway
On-site parking is available at the hotel
train_2.c46ac37e7110

From Other UK Cities

For guests travelling from outside London:

  • Arrive at London Paddington Station
  • Continue via:
    • Heathrow Express (fastest option), or
    • Elizabeth line (cost-effective alternative)
  • Transfer to bus or taxi for the final leg

Accommodation Options

Explore recommended hotels near the venue.

Radisson Blu Hotel, London Heathrow Venue Hotel

Radisson Blu Hotel, London Heathrow

140 Bath Road, Hayes, Middlesex, UB3 5AW
venue for this event

 To book a room at this hotel, please click the button below 

Book a Room
accom 2

London Heathrow Mariott Hotel

Bath Road Heathrow, Airport, Hayes UB3 5AN
4 minute walk from venue

 To book a room at this hotel, please click the button below 

Book a Room
accom 3

Ibis Style London Heathrow Airport

272 Bath Rd, London UB3 5AY
8 minute walk from venue

 To book a room at this hotel, please click the button below 

Book a Room
accom 4

Premier Inn London Heathrow

15 Bath Rd, London TW6 2AB
5 minute drive from venue

 To book a room at this hotel, please click the button below 

Book a Room
Event venue floorplan

Virtual Tour of Commonwealth Suite Virtual Tour of the Atrium Virtual Tour of Royal Suite
Please find the booth allocation in the table below.
4 Alfa Laval 11 QuickSTAT 12 BSP Pharmaceuticals 14 AsTec Chemicals 17 Unchained Labs 19 Inprocess LSP 18 Kemwell Biopharma